BioWorld MedTech

Feb. 11, 2015

Agendia receives new FDA clearance for MammaPrint

Molecular diagnostics company Agendia (Irvine, California) reported that it has received FDA 510(k) clearance for its MammaPrint breast cancer recurrence test in FFPE (formalin-fixed paraffin embedded) tissue. Read More

Latin America: Venezuela turns to China to alleviate medical device shortage

MDD Interview: French crowds say 'oui' to funding as EyeBrain raises $1.5 million

Inside the Beltway: AdvaMed highlights coverage of FDA-approved medical device trials

World in Review: Data from British Journal of Surgery supports Medtronic's ClosureFast

Seeking tax reform, U.S. Senate committee examines 1986 overhaul

Agreements/contracts: CWRU, Cleveland Clinic win DoD bid for prosthetic limb research

Financings: AxoGen closes public offering of stock for around $13 million

People in Places

Patent Watch: HCi Viocare files application for wearable devices, motion capture

Product Briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for March 19, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 17, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...